TriSalus Life Sciences Reports Preliminary Q4 Sales Of Approximately $5.7M, Representing 77% Growth Versus 2022; Est $5.453M
Portfolio Pulse from Benzinga Newsdesk
TriSalus Life Sciences announced preliminary Q4 sales of around $5.7M, marking a 77% increase compared to 2022, with an estimated $5.453M. For 2023, the company forecasts revenues of about $18.5M, a 49% growth from 2022, and anticipates a gross margin of 90% for Q4 and 86% for the full year.
March 11, 2024 | 9:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TriSalus Life Sciences expects significant revenue growth and high gross margins in Q4 and the full year 2023.
The reported and forecasted growth in sales and high gross margins for TriSalus Life Sciences indicate a strong financial performance and operational efficiency. This positive outlook is likely to attract investor interest and could lead to an increase in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100